Gryphon Financial Partners LLC Acquires 2,101 Shares of Johnson & Johnson (NYSE:JNJ)

Gryphon Financial Partners LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 14.0% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 17,122 shares of the company’s stock after buying an additional 2,101 shares during the quarter. Gryphon Financial Partners LLC’s holdings in Johnson & Johnson were worth $2,476,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. IFS Advisors LLC grew its stake in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares during the last quarter. Bay Harbor Wealth Management LLC bought a new stake in Johnson & Johnson during the fourth quarter worth about $32,000. RPg Family Wealth Advisory LLC bought a new stake in Johnson & Johnson during the third quarter worth about $35,000. Activest Wealth Management bought a new stake in Johnson & Johnson during the third quarter worth about $40,000. Finally, Fiduciary Advisors Inc. bought a new stake in Johnson & Johnson during the fourth quarter worth about $43,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Down 1.1 %

JNJ opened at $165.48 on Wednesday. The firm’s fifty day moving average is $151.73 and its two-hundred day moving average is $156.12. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a market cap of $398.41 billion, a PE ratio of 24.88, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period last year, the business posted $2.29 earnings per share. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. Equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were issued a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.00%. Johnson & Johnson’s payout ratio is 74.59%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on JNJ shares. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Wells Fargo & Company decreased their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Stifel Nicolaus decreased their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Insider Activity at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.